) announced that its ISO-Gard Mask with ClearAir Technology will
be used for the first time by the Community Surgery Center North
healthcare facility, part of Indianapolis, Indiana-based
Community Health Network.
ANGIODYNAMICS (ANGO): Free Stock Analysis
NATUS MEDICAL (BABY): Free Stock Analysis
CRYOLIFE INC (CRY): Free Stock Analysis
TELEFLEX INC (TFX): Free Stock Analysis
To read this article on Zacks.com click here.
The ISO-Gard Mask has been developed to protect nursing staffs in
the Post Anesthesia Care Unit (PACU) against harmful waste
anesthetic gas (WAG). As per the Occupational Safety and Health
Administration (OSHA), WAG exposure can lead to health problems
such as nausea, dizziness, headaches and fatigue. Moreover, the
ClearAir Technology featured with the ISO-Gard delivers oxygen to
patients and prevents their infectious exhalation from affecting
clinicians at the same time.
Based on a survey by the Centers for Disease Control and
Prevention (CDC), Teleflex projects that, every year, anesthetic
gases are used in 20 million surgeries in the U.S. and about 100
million worldwide. Adoption of the only remedy for "source
control" of WAG by medical centers should further boost revenues
of TFX's Anesthesia and Respiratory Division.
Headquartered in Limerick, PA, TFX is a leading provider of
specialty medical devices for a range of procedures in critical
care and surgery globally. Teleflex posted a 26.7% rise in
adjusted earnings to $1.33 per share for the third quarter of
2013 from $1.05 in the same quarter of 2012. With this, earnings
significantly beat the Zacks Consensus Estimate of $1.14. Net
revenues went up 12.4% to $413.8 million, exceeding the Zacks
Consensus Estimate of $410 million.
We are encouraged about its significant earnings beat in the
third quarter of 2013 and higher EPS guidance. However, we are
concerned about weaknesses in Asia and some of its product
markets that led to lower revenue guidance.
In the last reported quarter, revenues from Teleflex's core
Critical Care products (that includes anesthesia and respiratory
products) increased 18.7% to $289.3 million due to higher sales
of anesthesia, vascular, urology and interventional access
products. The rise in anesthesia product sales was attributable
to the contribution from the LMA International business,
partially offset by lower sales of respiratory products compared
with the third quarter of 2012.
Currently, TFX retains a Zacks Rank #3 (Hold). Stocks that are
performing relatively well in the medical instruments industry
Natus Medical Inc.
). While CryoLife and Natus Medical carry a Zacks Rank #1 (Strong
Buy), AngioDynamics carries a Zacks Rank #2 (Buy).